Etavopivat

N/A

Report date: 2026/04/08 20:02:35
NME

Base Information

Drug NameEtavopivat
Drug Alias NameFT-4202NN 7535NN 7536NN7535(Etavopivat in SCD)NN7535(Etavopivat in Sickle cell disease) +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPyruvate kinase activators
TargetsPyruvate kinase
Therapy Area/IndicationsMyelodysplastic Syndromesbeta-ThalassemiaThalassemia +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[23] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesForma Therapeutics Holdings Inc
China Registration ClassN/A

Develop Information

Active CompaniesForma Therapeutics Holdings IncNovo Nordisk A/SNovo Nordisk (China)Pharmaceuticals Co Ltd +[4] 
Inactive CompaniesN/A
Active Indicationsbeta-ThalassemiaThalassemiaAnemia, Sickle Cell +[4] 
Inactive IndicationsMyelodysplastic Syndromes

Other Information

ATC CodeN/A
Related LinksN/A